Langerhans cell histiocytosis.
Carlos Rodriguez-Galindo, Carl E Allen
https://pubmed.ncbi.nlm.nih.gov/32106306/Actively Recruiting
Led by West China Second University Hospital · Updated on 2025-06-15
20
Participants Needed
1
Research Sites
104 weeks
Total Duration
Langerhans cell histiocytosis LCH is a rare inflammatory tumor mostly affecting children, with symptoms ranging from mild to severe organ involvement. High-risk cases, involving liver, spleen, or blood system, have poorer outcomes and a higher chance of disease returning or progressing despite standard treatments like prednisone and vinblastine. Newer treatments such as cladribine and MAPK inhibitors have improved survival, but many patients still face challenges with disease resistance and recurrence. This study evaluates the combination of dabrafenib or trametinib both MAPK inhibitors with clofarabine, a chemotherapy drug, in children with high-risk, recurrent, or refractory LCH. Dabrafenib is given at 3-5 mgkgday or trametinib at 0.025 mgkgday, while clofarabine is administered as consolidation therapy at 25 mgm2day for 5 days and maintenance therapy at 25 mgm2day for 2 days. The trial aims to determine the safety and effectiveness of this combined treatment approach in these pediatric patients. Participants will be monitored for disease progression, treatment response, and side effects over time. The primary outcome is progression-free survival at 24 months, with secondary measures including overall response rates at 3 months and assessment of adverse events over 18 months. Children will undergo regular evaluations to track treatment impact and safety, with follow-up continuing to assess long-term outcomes throughout the study period ending in 2030.
CONDITIONS
Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children
X
Xue Tang, MD
X
Xia Guo, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
West China Second University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration determined by treatment cycles and clinical response
Participants receive Dabrafenib or Trametinib combined with Clofarabine as treatment for high-risk, recurrent, or refractory Langerhans Cell Histiocytosis.
Visits scheduled according to treatment cycles and clinical assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Carlos Rodriguez-Galindo, Carl E Allen
https://pubmed.ncbi.nlm.nih.gov/32106306/Jean Donadieu, Islam Amine Larabi, Mathilde Tardieu...
https://pubmed.ncbi.nlm.nih.gov/31513482/Riccardo Haupt, Vasanta Nanduri, Maria Grazia Calevo...
https://pubmed.ncbi.nlm.nih.gov/15049016/Vivekanudeep Karri, Howard Lin, Jessica Velazquez...
https://pubmed.ncbi.nlm.nih.gov/38501390/Dmitry Evseev, Daria Osipova, Irina Kalinina...
https://pubmed.ncbi.nlm.nih.gov/37216396/Carlos Rodriguez-Galindo, Michael Jeng, Phuong Khuu...
https://pubmed.ncbi.nlm.nih.gov/18623218/Sheila Weitzman, Jorge Braier, Jean Donadieu...
https://pubmed.ncbi.nlm.nih.gov/19731321/Allistair Abraham, Abdulrahman Alsultan, Michael Jeng...
https://pubmed.ncbi.nlm.nih.gov/23255383/James A Whitlock, Birgit Geoerger, Ira J Dunkel...
https://pubmed.ncbi.nlm.nih.gov/36884302/Helmut Gadner, Milen Minkov, Nicole Grois...
https://pubmed.ncbi.nlm.nih.gov/23589673/West China Second University Hospital
Lead Sponsor